Madrigal Pharmaceuticals price target lowered to $350 from $375 at Oppenheimer
Oppenheimer lowered the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $350 from $375 and keeps an Outperform rating on the ...
MyChesCo on MSN51m
Madrigal Pharmaceuticals Advances NASH Treatment with Full Enrollment of MAESTRO-NASH OUTCOMES Trial
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has successfully completed enrollment for its MAESTRO-NASH OUTCOMES trial, a ...
Business Insider11h
Madrigal Pharmaceuticals (MDGL) Gets a Buy from Oppenheimer
Oppenheimer analyst Jay Olson maintained a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report) today and set a price target of $350.00. The company’s shares closed yesterday at $203.59.
Madrigal Pharmaceuticals enrols patients in Phase III trial of NASH cirrhosis drug
Patients with well-compensated NASH cirrhosis and three metabolic risk factors were selected for inclusion in the study.
MyChesCo on MSN4d
Madrigal Pharmaceuticals Set to Reveal Q3 2024 Financial Results
CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) has announced that it will release its third-quarter 2024 ...
Prothena: Delays And Data Uncertainty Undermine Case For Investing (Downgrade)
Prothena Corporation plc's stock has dropped 67% since my last “Buy” rating, primarily due to delays and a lack of meaningful ...